ALK Inhibitor 1 is primarily used in the field of oncology for the treatment of cancers associated with alterations in the ALK (Anaplastic Lymphoma Kinase) gene. It is particularly effective in targeting non-small cell lung cancer (NSCLC) where ALK rearrangements are prevalent. By inhibiting the ALK protein, this compound helps to halt the proliferation of cancer cells and can induce apoptosis, thereby slowing tumor growth. Additionally, it is being explored for its potential in treating other ALK-positive malignancies such as anaplastic large cell lymphoma and neuroblastoma. Its application in clinical settings often involves combination therapies to enhance efficacy and overcome resistance mechanisms.